Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01892423
Other study ID # GLI.04SPR.US10044
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 2006

Study information

Verified date June 2013
Source Galderma R&D
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Human repeat insult patch test to assess the potential for Cetaphil Moisturizing Lotion Daily Advance to induce sensitization to the skin


Recruitment information / eligibility

Status Completed
Enrollment 146
Est. completion date
Est. primary completion date September 2006
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Age 18-65 years - Good health - willingness to cooperate and participate - willingness to avoid topical products at test sites - willingness to avoid direct sun exposure to test sites Exclusion Criteria: - Individuals with active psoriasis or eczema - individuals with sunburn, acne, abrasions, scar tissue, or tattoos on test sites, or disease of skin that might interfere - individuals who have had a mastectomy with axillary nodes were removed - individuals receiving anticancer, immunosuppressive treatments or medications, or radiation - pregnant, nursing, or planned to become pregnant - use of topical steroids or drugs at test sites - active or untreated skin cancer - active hepatitis - current routine or frequent use of high doses of anti-inflammatory drugs - individuals who have had les than two week rest period since completion of previous patch testing on upper back or upper arms - individuals with uncontrolled metabolic diseases

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Cetaphil Moisturizing Lotion Daily Advance


Locations

Country Name City State
United States Thomas J Stephens and Associates Inc Carrollton Texas

Sponsors (1)

Lead Sponsor Collaborator
Galderma R&D

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Irritation responses all patients will be assessed at 14 visits for redness (erythema), spreading, weeping, papules, vesicles, and bullae at application site average of 5 weeks
See also
  Status Clinical Trial Phase
Completed NCT01806831 - Efficacy and Safety of Biocellulose Sheet Containing Anti-hyperpigmentation Agent ("Biocellulose Mask", "Farhorm®") in Patients Receiving Laser Treatment N/A
Completed NCT02297841 - Repeated Insult Patch Test of Personal Lubricants N/A
Completed NCT02968446 - Effect of Vitamin D After Application With Valchlor Early Phase 1
Completed NCT03397862 - A Skin Irritation Assessment of Once-Weekly Corplex™ Donepezil Transdermal Delivery System Phase 1
Unknown status NCT01821274 - A 21-Day Topical Safety Study of Diltiazem Hydrochloride Using a Cumulative Irritant Patch Test Design Phase 1
Completed NCT01892657 - Cetaphil® Daily Facial Moisturizer With Sunscreen SPF 50+ - Human Repeat Insult Patch Test Phase 4
Withdrawn NCT02400320 - Local Skin Safety Study of a Topical Pain Relief Spray Containing a Combination of Diclofenac, Methyl Salicylate, and Menthol Phase 4
Not yet recruiting NCT02645110 - Evaluation of Effectiveness and Mildness of Whole-natural Hand-wash Formulations N/A
Completed NCT01887860 - Patch Test Skin Irritation/Sensitization of Cetaphil Daily Facial Moisturizer SPF 50 N/A
Completed NCT01892410 - Patch Test Skin Irritation/Sensitization of Cetaphil Restoraderm Skin Restoring Body Wash N/A
Completed NCT01888887 - Repeat Insult Patch Test of Skin Irritation/Sensitization for Cetaphil Daily Facial Cleanser N/A
Completed NCT01887808 - Repeat Insult Patch Test of Skin Irritation/Sensitization for Cetaphil Dermacontrol Oil Control Moisturizer SPF 30 N/A